OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers
Diego Orsini, Luigi Gargiulo, Luciano Ibba, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 15
Diego Orsini, Luigi Gargiulo, Luciano Ibba, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 15
Showing 15 citing articles:
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024052-e2024052
Open Access | Times Cited: 17
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024052-e2024052
Open Access | Times Cited: 17
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 495-495
Open Access | Times Cited: 8
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 495-495
Open Access | Times Cited: 8
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)
Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 7
Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 7
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study
Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 6, pp. 839-843
Open Access | Times Cited: 6
Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 6, pp. 839-843
Open Access | Times Cited: 6
Metabolic Disorders and Psoriasis: Exploring the Role of Nutritional Interventions
Marco Cintoni, Marta Palombaro, Fabio Stefano Maramao, et al.
Nutrients (2023) Vol. 15, Iss. 18, pp. 3876-3876
Open Access | Times Cited: 14
Marco Cintoni, Marta Palombaro, Fabio Stefano Maramao, et al.
Nutrients (2023) Vol. 15, Iss. 18, pp. 3876-3876
Open Access | Times Cited: 14
A risankizumab super responder profile identified by long‐term real‐life observation‐IL PSO (ITALIAN LANDSCAPE PSORIASIS )
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 10
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 10
Hard-to-Treat Areas in Psoriasis: An Underevaluated Part of the Disease
Adina-Mihaela Lupulescu, A. Savu, Ștefana Bucur, et al.
Life (2025) Vol. 15, Iss. 3, pp. 425-425
Open Access
Adina-Mihaela Lupulescu, A. Savu, Ștefana Bucur, et al.
Life (2025) Vol. 15, Iss. 3, pp. 425-425
Open Access
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study
Luciano Ibba, S. Di Giulio, Luigi Gargiulo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 2
Luciano Ibba, S. Di Giulio, Luigi Gargiulo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 2
Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)
Diego Orsini, Chiara Assorgi, Claudio Bonifati, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Diego Orsini, Chiara Assorgi, Claudio Bonifati, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areas
Angela Michelucci, Flavia Manzo Margiotta, Alessandra Cartocci, et al.
Archives of Dermatological Research (2024) Vol. 316, Iss. 6
Closed Access | Times Cited: 1
Angela Michelucci, Flavia Manzo Margiotta, Alessandra Cartocci, et al.
Archives of Dermatological Research (2024) Vol. 316, Iss. 6
Closed Access | Times Cited: 1
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement
Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. 1150-1157
Open Access | Times Cited: 1
Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. 1150-1157
Open Access | Times Cited: 1
Risankizumab for the treatment of genital psoriasis: A 1‐year, real‐world experience
Diego Orsini, Pasquale Frascione, Chiara Assorgi, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 3
Closed Access | Times Cited: 3
Diego Orsini, Pasquale Frascione, Chiara Assorgi, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 3
Closed Access | Times Cited: 3
Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis
Sotirios G. Tsiogkas, Maria G. Grammatikopoulou, Katerina‐Maria Kontouli, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 12, pp. 1485-1498
Closed Access | Times Cited: 3
Sotirios G. Tsiogkas, Maria G. Grammatikopoulou, Katerina‐Maria Kontouli, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 12, pp. 1485-1498
Closed Access | Times Cited: 3
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 11, pp. 2987-2997
Open Access
Mario Valenti, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 11, pp. 2987-2997
Open Access
Acrodermatitis continua of Hallopeau in an elderly patient successfully and rapidly treated with risankizumab: a case report
Diego Orsini, Paolo Iacovelli, Pasquale Frascione, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access
Diego Orsini, Paolo Iacovelli, Pasquale Frascione, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access
